

if pregnant, call Antiretroviral Pregnancy Registry, 1-800-258-4263

- PR interval in those taking calcium channel blockers, digoxin
- For signs of infection, anemia, nephrolithiasis
- Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration
- Viral load, CD4 count throughout treatment

• **Serious rash (Stevens-Johnson syndrome, DRESS):** most rashes last 1-4 wk; if serious, discontinue product

- **Pregnancy/breastfeeding:** no well-controlled studies; use only if benefit outweighs fetal risk; if pregnant, call Antiretroviral Pregnancy Registry, 800-258-4263; avoid use in breastfeeding

Evaluate:

- Therapeutic response: increasing CD4 counts; decreased viral load, resolution of symptoms of HIV-1 infection

Teach patient/family:

- To take as prescribed with other antiretrovirals as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose, share with others
- That product must be taken daily to maintain blood levels for duration of therapy
- To report yellowing of skin, sclera
- To notify prescriber if diarrhea, nausea, vomiting, or rash occurs; dizziness, lightheadedness may occur; ECG may be altered
- That product interacts with many products, including St. John's wort; to advise prescriber of all products, herbal products used
- That redistribution of body fat may occur, the effect is not known
- That product does not cure HIV-1 infection, prevent transmission to others; only controls symptoms
- **That, if taking phosphodiesterase type 5 inhibitor with atazanavir, there may be increased risk of phosphodiesterase type 5 inhibitor-associated adverse events (hypotension, prolonged penile erection);**

to notify physician promptly of these symptoms

RARELY USED

dasatinib (Rx)

(da-si'ti-nib)

Sprycel

Func. class.: Antineoplastic—miscellaneous

Chem. class.: Protein-tyrosine kinase inhibitor

USES: Treatment of accelerated, chronic blast phase CML or acute lymphoblastic leukemia (ALL); chronic phase CML with resistance or intolerance to prior therapy; Philadelphia chromosome-positive CML in chronic phase

CONTRAINDICATIONS: Pregnancy, hypersensitivity

DOSAGE AND ROUTES

Accelerated or myeloid/lymphoid blast phase CML with resistance/intolerance to prior therapy

- **Adult: PO** 140 mg daily titrated up to 180 mg daily in those resistant to therapy

Chronic phase CML with resistance/intolerance to prior therapy

- **Adult: PO** 100 mg daily either AM OR PM

Dosage reduction for those taking a strong CYP3A4 inhibitor

- **Adult: PO** 20-40 mg daily

⚠ HIGH ALERT

DAUNOrubicin (Rx)

(daw-noe-roo'bi-sin)

Cerubidine

Func. class.: Antineoplastic, antibiotic

Chem. class.: Anthracycline glycoside

Do not confuse:

DAUNOrubicin/DOXOrubicin

ACTION: Inhibits DNA synthesis, primarily; derived from *Streptomyces coeruleorubidus*; replication is decreased by